A novel VEGF targeted agent to discover the future perspectives of

A novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of several tumors. Mini Rev Med Chem 2013, 13(four):53040. 52. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al: VEGFTrap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99(17):113931398. 53. Konner J, Dupont J: Use of soluble recombinant decoy VEGF trap to inhibit VEGF activity. Clin Colorectal Cancer 2004, 4:S81 85. 54. Lassoued W, Murphy D, Tsai J, Oueslati R, Thurston G, Lee WM: Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther 2011, ten(12):1326333. 55. Maulik G, Shrikhande A, Kijima T, Ma Pc, Morrison PT, Salgia R: Function from the hepatocyte development aspect receptor, c-Met, in oncogenesis and possible for therapeutic inhibition. Cytokine Growth Element Rev 2002, 13(1):41. 56. Galland F, Stefanova M, Lafage M, Birnbaum D: Localization of your 5’end of the MCF2 oncogene to human chromosome 15q15 q23. Cytogenet Genome Res 1992, 60(2):11416. 57. Comoglio PM, Giordano S, Trusolino L: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008, 7(6):50416. 58. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H, et al: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85(9):1894902. 59. Dussault I, Bellon SF: From notion to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the remedy of cancer. AntiCancer Agents Med Chem 2009, 9(2):22129. 60. Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC: Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition issue (c-Met) protein autophosphorylation by ARQ 197.Ertapenem sodium J Biol Chem 2011, 286(23):206660676. 61. Underiner TL, Herbertz T, Miknyoczki SJ: Discovery of little molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anti-Cancer Agents Med Chem 2010, ten(1):7. 62. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, et al: Phase II and biomarker study of your dual MET/VEGFR2inhibitor foretinib in individuals with papillary renal cell carcinoma. J Clin Oncol 2013, 31(2):18186. 63. Muro K, Ryu MH, Yasui H, Nishina T, Ryoo BY, Boku N, Kang YK: A phase II study of tivantinib monotherapy in sufferers with previously treated sophisticated or recurrent gastric cancer [abstract].Nipocalimab J Clin Oncol 2012 (suppl):4082.PMID:24914310 http://www.asco.org/. 64. Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4(5):33548. 65. Mart ME, MI P’ r, Redondo C, Alvarez MI, Salinas M, Fando JL: 4E binding protein 1 expression is inversely correlated for the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000, 32(6):63342. 66. Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V: Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 2008, 7(9):1377385. 67. Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K, Nakagawa K: Phase I clinical and pharmacokinetic study of RAD001 (Everolimus) administered each day to Japanese patients wi.